In January 2010, the US Food and Drug Administration (FDA) issued a Med Watch alert notifying health care professionals of the necessity to communicate with local laboratories regarding the assay method used to measure sirolimus concentrations. As chromatographic and immunoassay technologies are not interchangeable, patient care may be compromised if patients are not consistently monitored with one assay type. Pharmacists should investigate which assay method is employed by their institutions, whether changes in assay type have occurred, and whether the reference ranges for their institution or referring centers have been modified.
展开▼
